Literature DB >> 25218173

Cardiomyocyte intracellular cholesteryl ester accumulation promotes tropoelastin physical alteration and degradation: Role of LRP1 and cathepsin S.

Valerie Samouillan1, Elena Revuelta-López2, Jany Dandurand3, Laura Nasarre2, Lina Badimon2, Colette Lacabanne3, Vicenta Llorente-Cortés4.   

Abstract

Dyslipemia has a direct impact on cardiac remodeling by altering extracellular matrix (ECM) components. One of the main ECM components is elastin, a proteic three-dimensional network that can be efficiently degraded by cysteine proteases or cathepsins. Dyslipemic status in insulin resistance and combined hyperlipoproteinemia diseases include raised levels of very low density lipoproteins (VLDL), triglyceride (TG)-cholesteryl ester (CE)-rich lipoproteins. Enhanced VLDL concentration promotes cardiomyocyte intracellular cholesteryl ester (CE) accumulation in a LRP1-dependent manner. The aim of this work was to analyze the effect of cardiomyocyte intracellular CE accumulation on tropoelastin (TE) characteristics and to investigate the role of LRP1 and cathepsin S (CatS) on these effects. Molecular studies showed that LRP1 deficiency impaired CE selective uptake and accumulation from TG-CE-rich lipoproteins (VLDL+IDL) and CE-rich lipoproteins (aggregated LDL, agLDL). Biochemical and confocal microscopic studies showed that LRP1-mediated intracellular CE accumulation increased CatS mature protein levels and induced an altered intracellular TE globule structure. Biophysical studies evidenced that LRP1-mediated intracellular CE accumulation caused a significant drop of Tg2 glass transition temperature of cardiomyocyte secreted TE. Moreover, CatS deficiency prevented the alterations in TE intracellular globule structure and on TE glass transition temperature. These results demonstrate that LRP1-mediated cardiomyocyte intracellular CE accumulation alters the structural and physical characteristics of secreted TE through an increase in CatS mature protein levels. Therefore, the modulation of LRP1-mediated intracellular CE accumulation in cardiomyocytes could impact pathological ventricular remodeling associated with insulin-resistance and combined hyperlipoproteinemia, pathologies characterized by enhanced concentrations of TG-CE-rich lipoproteins.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cardiac remodeling; Cardiomyocyte; Cathepsin S; Intracellular cholesterol esters; Tropoelastin; VLDL

Mesh:

Substances:

Year:  2014        PMID: 25218173     DOI: 10.1016/j.biocel.2014.09.005

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  11 in total

1.  Differential cathepsin responses to inhibitor-induced feedback: E-64 and cystatin C elevate active cathepsin S and suppress active cathepsin L in breast cancer cells.

Authors:  Catera L Wilder; Charlene Walton; Valencia Watson; Fermin A A Stewart; Jade Johnson; Shelly R Peyton; Christine K Payne; Valerie Odero-Marah; Manu O Platt
Journal:  Int J Biochem Cell Biol       Date:  2016-08-31       Impact factor: 5.085

2.  Evaluating the diagnostic and prognostic value of circulating cathepsin S in gastric cancer.

Authors:  Wan-Li Liu; Dan Liu; Kai Cheng; Yi-Jun Liu; Shan Xing; Pei-Dong Chi; Xiao-Hua Liu; Ning Xue; Yan-Zhen Lai; Ling Guo; Ge Zhang
Journal:  Oncotarget       Date:  2016-05-10

3.  Relationship among LRP1 expression, Pyk2 phosphorylation and MMP-9 activation in left ventricular remodelling after myocardial infarction.

Authors:  Elena Revuelta-López; Carol Soler-Botija; Laura Nasarre; Aleyda Benitez-Amaro; David de Gonzalo-Calvo; Antoni Bayes-Genis; Vicenta Llorente-Cortés
Journal:  J Cell Mol Med       Date:  2017-04-04       Impact factor: 5.310

4.  Serum microRNA-1 and microRNA-133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes.

Authors:  D de Gonzalo-Calvo; R W van der Meer; L J Rijzewijk; J W A Smit; E Revuelta-Lopez; L Nasarre; J C Escola-Gil; H J Lamb; V Llorente-Cortes
Journal:  Sci Rep       Date:  2017-03-03       Impact factor: 4.379

5.  Identification of new biophysical markers for pathological ventricular remodelling in tachycardia-induced dilated cardiomyopathy.

Authors:  Aleyda Benitez-Amaro; Valerie Samouillan; Esther Jorge; Jany Dandurand; Laura Nasarre; David de Gonzalo-Calvo; Olga Bornachea; Gerard Amoros-Figueras; Colette Lacabanne; David Vilades; Ruben Leta; Francesc Carreras; Alberto Gallardo; Enrique Lerma; Juan Cinca; Jose M Guerra; Vicenta Llorente-Cortés
Journal:  J Cell Mol Med       Date:  2018-06-19       Impact factor: 5.310

Review 6.  The Role of Low-Density Lipoprotein Receptor-Related Protein 1 in Lipid Metabolism, Glucose Homeostasis and Inflammation.

Authors:  Virginia Actis Dato; Gustavo Alberto Chiabrando
Journal:  Int J Mol Sci       Date:  2018-06-15       Impact factor: 5.923

Review 7.  Developing LRP1 Agonists into a Therapeutic Strategy in Acute Myocardial Infarction.

Authors:  Nicola Potere; Marco Giuseppe Del Buono; Giampaolo Niccoli; Filippo Crea; Stefano Toldo; Antonio Abbate
Journal:  Int J Mol Sci       Date:  2019-01-28       Impact factor: 5.923

Review 8.  Low Density Lipoprotein Receptor-Related Protein-1 in Cardiac Inflammation and Infarct Healing.

Authors:  Nicola Potere; Marco Giuseppe Del Buono; Adolfo Gabriele Mauro; Antonio Abbate; Stefano Toldo
Journal:  Front Cardiovasc Med       Date:  2019-04-26

9.  LRP1-Mediated AggLDL Endocytosis Promotes Cholesteryl Ester Accumulation and Impairs Insulin Response in HL-1 Cells.

Authors:  Virginia Actis Dato; Aleyda Benitez-Amaro; David de Gonzalo-Calvo; Maximiliano Vazquez; Gustavo Bonacci; Vicenta Llorente-Cortés; Gustavo Alberto Chiabrando
Journal:  Cells       Date:  2020-01-10       Impact factor: 6.600

10.  Soluble LRP1 is an independent biomarker of epicardial fat volume in patients with type 1 diabetes mellitus.

Authors:  David de Gonzalo-Calvo; Cristina Colom; David Vilades; Andrea Rivas-Urbina; Abdel-Hakim Moustafa; Montserrat Pérez-Cuellar; Jose Luis Sánchez-Quesada; Antonio Pérez; Vicenta LLorente-Cortes
Journal:  Sci Rep       Date:  2018-01-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.